Table 4.
Treatment | N |
---|---|
Steroids2 4 7–12 14–19 22–24 26 27 29 31 33 34 | 29 (52%) |
Antibiotics (treatment or prophylactic)4 9 11–13 16 18 20 26 28 32 | 14 (25%) |
Antihistamine2 10 11 16 20 23 27 28 31–33 | 14 (25%) |
Surgery (excluding bladder biopsies/resection of bladder lesions)2 13 17 19–21 | 8 (14%) |
NSAID7 10 20 33 | 5 (9%) |
No treatment13 25 | 4 (7%) |
Antiparasitic medication8 28 32 | 3 (5%) |
Montelucast8 18 | 2 (4%) |
Infravesical sodium pentosan polysulfate17 31 | 2 (4%) |
Spasmolytic10 13 | 2 (4%) |
Infravesical steroid17 32 | 2 (4%) |
α-receptor blocker25 27 | 2 (4%) |
TUR-B15 16 | 2 (4%) |
Gabapentine31 | 1 (2%) |
Nephrostomy15 | 1 (2%) |
Ciclosporin23 | 1 (2%) |
Sodium chromoglycate7 | 1 (2%) |
Suplatast tosilate (cytokine inhibitor)9 | 1 (2%) |
NSAID, non-steroidal anti-inflammatory drug.